Comparison of a new serum topiramate immunoassay to fluorescence polarization immunoassay

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 107-111

  Snozek, Christine L H ^a   Rollins, Lisa A ^a   Peterson, Paul W ^a   Langman, Loralie J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anticonvulsant; FPIA; Immunoassay; Topiramate

Indexed keywords

TOPIRAMATE;

ARK IMMUNOASSAY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTICONVULSANTS; FLUORESCENCE POLARIZATION IMMUNOASSAY; FRUCTOSE; HUMANS; IMMUNOASSAY;

EID: 75649094859     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c4cebb     Document Type: Article

References (5)

1. Topiramate. In: in the Physicians' Desk Reference (online). Available at: http://www.thomsonhc.com/clinicalxpert/librarian. Accessed July 24, 2009.
2. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45:1061-1075.
3. LaRoche SM. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist. 2007;13:133-139.
4. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.
5. Christensen J, Hojskov CS, Poulsen JH. Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: validation and comparison with fluorescence-polarization immunoassay. Ther Drug Monit. 2002;24:658-664.